Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
See All Experts
story of the week
Published in Oncology and
1 other channel

Journal Scan / Research · September 17, 2020

Tumor Mutational Burden Associated With Outcomes in Patients With Advanced Solid Tumors Treated With Pembrolizumab

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Paul Hampel MD

The Lancet Oncology
Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study
Lancet Oncol 2020 Sep 10;[EPub Ahead of Print], A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, K Nakagawa, HC Chung, HL Kindler, JA Lopez-Martin, WH Miller, A Italiano, S Kao, SA Piha-Paul, JP Delord, RR McWilliams, DA Fabrizio, D Aurora-Garg, L Xu, F Jin, K Norwood, YJ Bang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated